Welcome!

News Feed Item

Drug Discovery Technologies - A Global Market Overview

NEW YORK, Sept. 1, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:  Drug Discovery Technologies - A Global Market Overview

http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html

The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening.

Worldwide market for drug discovery technologies explored in this study includes Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Others comprising Epigenetics, Metabolomics, Combinatorial Chemistry, Synthetic Biology, Systems Biology and Nanotechnology.

The global market value for the above mentioned technologies is analyzed in USD. High Throughput Screening accounts for a lion's share in global drug discovery technologies market with an expected share of about 30% in 2015 valued at $18 billion followed by Bioanalytical Assays or instruments by about $14 billion.

This 248 pages global market report includes 28 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. This report profiles 56 key global players and 67 major players across the United States – 41; Europe – 16; Asia-Pacific – 7; and Rest of World - 3. The research also provides the listing of the companies that are engaged in technology, contract research services and providers of discovery technologies. The global list of companies covers addresses, contact numbers and the website addresses of 186 companies.

TABLE OF CONTENTS:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Product Outline

1.1.1 Backdrop

1.1.2 What Is Drug Discovery?

1.1.2.1 Screening and Design

1.1.3 Omics in Drug Discovery and Development

1.1.4 Process of Discovering Improved Drugs Provided by a Technological Revolution

1.1.5 Drug Discovery Technologies

1.1.5.1 Bioanalytical Assays

1.1.5.1.1 Bio-Analytical Techniques

1.1.5.1.2 Sample Extraction

1.1.5.2 Bioinformatics

1.1.5.2.1 Computer-Aided Drug Design

1.1.5.3 Cell Based Assays

1.1.5.3.1 Cell-Based Assays in High-Throughput Screening for Drug Discovery

1.1.5.4 Genomic Technologies

1.1.5.4.1 Drug Discovery

1.1.5.4.2 Clinical Medicine

1.1.5.4.3 New Antibiotics

1.1.5.5 High Throughput Screening

1.1.5.5.1 High Throughput Screening in Drug Discovery

1.1.5.6 Proteomic Technologies

1.1.5.6.1 A Proteomics Approach to Biomarker Discovery and Drug Development

1.1.5.7 Other Technologies

1.1.5.7.1 Epigenetics

1.1.5.7.1.1 Epigenetics and Cancer Treatment

1.1.5.7.2 Metabolomics

1.1.5.7.2.1 Target Identification

1.1.5.7.2.2 Target Validation

1.1.5.7.2.3 Lead Optimization

1.1.5.7.2.4 Mode of Action

1.1.5.7.2.5 Preclinical Studies

1.1.5.7.2.6 Clinical Studies

1.1.5.7.2.7 Post-Approval Studies

1.1.5.7.2.8 Diagnostics

1.1.5.7.3 Combinatorial Chemistry

1.1.5.7.3.1 Chemical Encoding

1.1.5.7.3.2 Positional Encoding

1.1.5.7.3.3 Electronic Encoding

1.1.5.7.4 Synthetic Biology

1.1.5.7.5 Systems Biology

1.1.5.7.5.1 Computer Modelling

1.1.5.7.6 Nanotechnology

2. KEY MARKET TRENDS

2.1 Drug Discovery Gets Faster, Smarter and Cheaper

2.2 Drug Discovery Being Enabled through Halogen Bonds

2.3 Drug Discovery Bolstered by New Use for Stem Cells in Targeting ALS

2.4 Personalized Medicine: Advantage Patients, Disadvantage Drug Companies

2.5 Identification of Diagnostic and Therapeutic Targets Better Enabled by Combining Plasma Screening and Genetic Screening

2.6 Source of New Drug Category from Trapping Malaria Parasites inside Host Blood Cell

2.7 Fighting Malaria Drug Resistance through an Innovative Method

2.8 Drug Screening in 3D Using High-Throughput Chip

2.9 Drug Discovery Expedited through 3D Protein Mapping

2.10 Drug Discovery and Automated Cell Staining

2.11 Drug Discovery and Development for Complex Disease Targets to be Alleviated through a Computer Program

3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE

USPTO Issues '979 Patent for Biohaven's Glutamate Modulating Agents to Treat GAD

Patents Issued for Suven's New Chemical Entities to treat Neurodegenerative Disorders

Japan Patent Office Approves Patent for C4XD's Technology

Additional Patents Issued on MorphoSys' Ylanthia in the US and in China

Sareum Receives a Patent for its Kinase Inhibitors in Japan

USPTO Grants Patent for Prima BioMed's CVac

Japan Patent Office Decides to Issue Patent for Marina's SMARTICLES® Nucleic Acid Delivery Technology

USPTO Grants a Patent in Regulus' Sarnow Patent Estate on microRNA Therapies to Treat HCV

USPTO Grants Patent for Kadimastem's Cell Technology

USPTO Grants a Novel Patent in Alnylam's McSwiggen Patent Estate

Suven Receives Patent Approval in the US for its Major Depressive Disorder Drug

Notice of Allowance for Canadian Patent Granted to VistaGen

Issue of Patent on Broad Institute's New Gene-Editing Method

US Patent Office Grants Patent for HUB's Method of Growing Organoids

Dyadic Granted US Patent for High Throughput Screening

US Patent Granted to Theranostics Health

Reveleris Flash Chromatography System Receives Patent from the Australian Patent Office

Sareum Receives Patent for one of its CHK1 Cancer Programme-related Inventions in the US

Lpath's iSONEP Receives Patent from USPTO

KeyGene Obtains Patent for High Throughput Screening in the US

BioInvent's F.I.R.S.T. Drug Discovery Technology Gets Patent in the US

Plasticell Receives Additional Patents for its CombiCult® Cell Culture Technology in the US, Europe, Australia and Singapore

EntomoPharm Receives Patent for its BBB Insect Model in Europe

Summit Gets Patent for Utrophin Modulator SMT C1100 in the US

USPTO Grants Patent to OncoMed for Methods of Treating Cancer with its Antibody Vantictumab

Novel Component of Phylomer® Peptide Platform Patented by Phylogica for Advanced Cell-Penetrating Drug Discovery

COTI Receives Two Newly Granted Patents for its Lead Oncology Asset in the US

4. KEY GLOBAL PLAYERS4-Antibody AGAbbott LaboratoriesAccelrys, Inc.Affymetrix Inc.Agilent Technologies Inc.Asahi Kasei Pharma CorporationAstrazeneca PlcAviva Biosciences Corp.Bayer Healthcare AGBD BiosciencesBeckman Coulter Inc.Biacore International ABBioanalytical Systems, Inc.Bio-Rad Laboratories, Inc.Boehringer Ingelheim GmbHBristol-Myers Squibb CompanyCaliper Life Sciences, Inc.Caprion Proteomics, Inc.Celera CorporationCelgene CorporationCharles River Laboratories International, Inc.Compugen Ltd.Decode Genetics, Inc.EMD Millipore CorporationEvotec AGGE Healthcare Ltd.Genedata AGHitgen LtdHudson Robotics, Inc.Illumina Inc.Incyte CorporationIsis Pharmaceuticals, Inc.Kyowa Hakko Kirin Co., Ltd.Luminex CorporationMaxcyte, IncMerck & Co., Inc.Millennium Pharmaceuticals, Inc.Molecular Devices, LLCMolecular Discovery Ltd.Molecular Discovery Systems Pty., Ltd.New England Biolabs, Inc.Novartis AGOsiris Therapeutics Inc.Perkinelmer, Inc.Promega CorporationQiagen N.V.Quantum PharmaceuticalsRoche Holding AGShimadzu CorporationSigma-Aldrich CorporationSri BiosciencesTecan Group Ltd.The National Center for Drug ScreeningThermo Fisher Scientific Inc.Viva Biotech LtdWaters Corp.

5. KEY BUSINESS TRENDS

Evotec Established Alliance with Eternygen on New Small Molecule Inhibitors Development

MRC Technology Partnered With Daiichi Sankyo to Discover New Drug Targets

Evotec, Debiopharm Group™ to Discover New Drugs to treat Cancer

Daiichi Sankyo Forms Alliance with UCSF on New Cures Development to Treat Neurodegenerative Diseases

Debut of a Synergetic Drug Discovery Project for 2014 by Daiichi Sankyo

Analgesic Drug Discovery and Development Collaboration Formed by Convergence and Evotec

MIT SBC, Pfizer Enter into a Three-Year Drug Discovery Research Alliance

Abide, Celgene Partners to Discover and Develop Novel Drugs to Treat Inflammation and Immunological Disorders

Novel Genetic Platform Having the Ability to Yield Natural Microbial Genomes

Johnson & Johnson Innovation Signs Novel Agreements with NEOMED and MaRS Innovation

Boehringer Ingelheim and Circuit Therapeutics Form Drug Discovery Research Pact for Three Years

Life Technologies and NCATS form RNAi Research Alliance to Enhance Novel Therapeutics Discovery

Novel Core Unit of USTAR and U of U Eases Pharmacological Therapeutic Development

JHL Biotech Inks Strategic Collaboration with Selexis to Develop Biologic Drugs

Bayer Offer Funding to the SGC for Expediting Drug Research

HitGen, the University of Manchester's Cancer Research UK Manchester Institute Drug Discovery Group and Cancer Research Technology Form Drug Discovery Pact

BioFocus, Boehringer Ingelheim Enter Into Drug Discovery Pact

Evotec Establishes Drug Discovery Alliance with Johnson & Johnson Innovation on AD Targets

Release of GE Healthcare Life Sciences' Novel Xuri™ Technology Family

4SC Discovery, CRELUX and AiCuris Form Drug Discovery Pact

Novel SLAP Technology for Drug Discovery Advancements

Inauguration of GE Healthcare Life Sciences Technology Laboratory at the UK's First Open Innovation Bioscience Campus

Debut of an "Open Innovation" Research Alliance by AstraZeneca and Taiwan's NRPB to Accelerate Drug Discovery

Asahi Kasei Pharma and Vernalis plc Collaborate to Discover Drugs for Autoimmune Diseases

Launch of Thermo Fisher Scientific's Novel Innovations at BioProcess International Conference and Exhibition

Adimab Establishes Alliance with Celgene on Multi-target Discovery

Eurofins Scientific, GE Healthcare Enter Pact on Drug Discovery Services

Debut of Boehringer Ingelheim and Polyphor into the Next Research Stage of their Alliance

Commercial Release of Agilent's RapidFire 365 High-Throughput Mass Spectrometry System

Zalicus Plans to Advance Clinical Development of Z944

Debut of Kinexus' DrugKiNET KnowledgeBase

Evotec Establishes Alliance with Harvard University to Develop Novel Antibacterial Agents

UCSF Turns to be the First Partner of Pfizer's CTI in Both Small-Molecule and Biologics Discovery

In-House Development of Various Novel Antiviral Drugs from Achillion

Launch of Thermo Fisher Scientific's Drug Discovery and Biopharma Production Innovations

Sareum Partners with SRI International for Advancing the Clinical Development of Tyrosine Kinase 2 Small Molecule Drug Discovery Program

Launch of Hudson Robotics' High Efficiency Screening, an Advanced Drug Discovery Technology

Accelrys Insight and Accelrys Insight for Excel Drug Discovery Softwares from Accelrys, Inc

Renewal of Evotec and Genentech's Drug Discovery Collaboration

Alchemia, AstraZeneca Form Multi-Target Drug Discovery Pact

RaQualia Establishes Research Alliance with Interprotein to Discover PPI Inhibitor

Collaborative Effort of Evotec and Ono Yields Novel Compounds for Preclinical Development

Galapagos Takeover Cangenix Assets

EMD Millipore's Novel Genomic Biomarker Services

Marketing of an Advanced Metabolite-Identification Platform by Agilent and Molecular Discovery

QuantiGene® ViewRNA Assay Platform-based Novel Cancer Biomarker Tests Co-developed by Affymetrix and MGH

Numerate and Merck Partnered to Discover Drug Leads for Cardiovascular Disease Target

Evotec Partners with IR Pharma to Offer Drug Discovery Solutions in the Area of Respiratory Diseases

6. GLOBAL MARKET OVERVIEW6.1. Global Market Overview by Technology6.1.1 Drug Discovery Technology Overview by Global Region6.1.1.1 Bioanalytical Assays6.1.1.2 Bioinformatics6.1.1.3 Cell Based Assays6.1.1.4 Genomic Technologies6.1.1.5 High Throughput Screening6.1.1.6 Proteomic Technologies6.1.1.7 Other Drug Discovery Technologies

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES

1.1 United States Market Overview by Technology

1.2 Major Market Players

Abbott Laboratories

Accelrys, Inc.

Affymetrix Inc.

Agenus Inc.

Agilent Technologies Inc.

Albany Molecular Research, Inc.

Arqule Inc.

Aviva Biosciences Corp.

BD Biosciences

Beckman Coulter Inc.

Bioanalytical Systems, Inc.

Bio-Rad Laboratories, Inc.

Biovision, Inc.

Bristol-Myers Squibb Company

Bruker Corporation

Caliper Life Sciences, Inc.

Capital Genomix, Inc.

Celera Corporation

Celgene Corporation

Charles River Laboratories International, Inc.

Discoverx Corporation

Discovery Genomics, Inc.

EMD Millipore Corporation

Hudson Robotics, Inc.

Illumina Inc.

Incyte Corporation

Isis Pharmaceuticals, Inc.

Life Technologies Corporation

Luminex Corporation

Maxcyte, Inc

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Molecular Devices, LLC

New England Biolabs, Inc.

Osiris Therapeutics Inc.

Perkinelmer, Inc.

Promega Corporation

Sigma-Aldrich Corporation

SRI Biosciences

Thermo Fisher Scientific Inc.

Waters Corp.

2. EUROPE2.1 European Market Overview by Technology2.2 Major Market Players4-Antibody AG (Switzerland)Astrazeneca Plc (United Kingdom)Bayer Healthcare AG (Germany)Biacore International AB (Sweden)Biofocus Dpi, Ltd (United Kingdom)Boehringer Ingelheim GmbH (Germany)Decode Genetics, Inc. (Iceland)Evotec AG (Germany)GE Healthcare Ltd. (United Kingdom)Genedata AG (Switzerland)Molecular Discovery Ltd. (Italy)Novartis AG (Switzerland)Qiagen N.V. (The Netherlands)Quantum Pharmaceuticals (Russia)Roche Holding AG (Switzerland)Tecan Group Ltd. (Switzerland)

3. ASIA-PACIFIC

3.1 Asia-Pacific Market Overview by Technology

3.2 Major Market Players

Asahi Kasei Pharma Corporation (Japan)

Hitgen Ltd (China)

Kyowa Hakko Kirin Co., Ltd. (Japan)

Molecular Discovery Systems Pty., Ltd. (Australia)

Shimadzu Corporation (Japan)

The National Center for Drug Screening (China)

Viva Biotech Ltd (China)

4. REST OF WORLD4.1 Rest of World Market Overview by Technology4.2 Major Market PlayersCaprion Proteomics, Inc. (Canada)Compugen Ltd. (Israel)Pluristem Therapeutics Inc. (Israel)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

1.1 Canada

1.2 United States

2. EUROPE

2.1 Belgium

2.2 Denmark

2.3 France

2.4 Germany

2.5 Iceland

2.6 Ireland

2.7 Italy

2.8 Russia

2.9 Sweden

2.10 Switzerland

2.11 The Netherlands

2.12 The United Kingdom

3. ASIA-PACIFIC

3.1 Australia

3.2 China

3.3 India

3.4 Japan

3.5 Singapore

3.6 Taiwan

4. REST OF WORLD

4.1 Israel

PART D: ANNEXURE1. RESEARCH METHOLOGY2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVEChart 1: Global Drug Discovery Technologies Market Analysis (2010-2020) in USD MillionChart 2: Global Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD MillionChart 3: Glance at 2010, 2015 and 2020 Global Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other TechnologiesChart 4: Global Market for Bioanalytical Assays in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 5: Glance at 2010, 2015 and 2020 Global Market Share of Bioanalytical Assays in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 6: Global Market for Bioinformatics in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 7: Glance at 2010, 2015 and 2020 Global Market Share of Bioinformatics in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 8: Global Market for Cell Based Assays in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 9: Glance at 2010, 2015 and 2020 Global Market Share of Cell Based Assays in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 10: Global Market for Genomic Technologies in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 11: Glance at 2010, 2015 and 2020 Global Market Share of Genomic Technologies in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 12: Global Market for High Throughput Screening in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 13: Glance at 2010, 2015 and 2020 Global Market Share of High Throughput Screening in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 14: Global Market for Proteomic Technologies in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 15: Glance at 2010, 2015 and 2020 Global Market Share of Proteomic Technologies in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 16: Global Market for Other Drug Discovery Technologies in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 17: Glance at 2010, 2015 and 2020 Global Market Share of Other Drug Discovery Technologies in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 18: The Projection of Largest Regions in terms of Market Growth for Drug Discovery Technologies by Geography – Asia-Pacific, Europe and United States

Chart 19: Global Drug Discovery Technologies Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 20: Glance at 2010, 2015 and 2020 Global Drug Discovery Technologies Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

THE UNITED STATESChart 21: United States Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD MillionChart 22: Glance at 2010, 2015 and 2020 United States Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

EUROPE

Chart 23: European Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD Million

Chart 24: Glance at 2010, 2015 and 2020 European Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

ASIA-PACIFICChart 25: Asia-Pacific Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD MillionChart 26: Glance at 2010, 2015 and 2020 Asia-Pacific Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

REST OF WORLD

Chart 27: Rest of World Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD Million

Chart 28: Glance at 2010, 2015 and 2020 Rest of World Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

Table 1: Prominent Technologies used for Bioanalytical ResearchTable 2: Prominent Types of Cell Based Assays used in High Throughput Screening

To order this report:  Drug Discovery Technologies - A Global Market Overview

http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html 

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution. In his session at @ThingsExpo, Akvelon expert and IoT industry leader Sergey Grebnov provided an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discussed how a new approach is neces...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abilit...
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
In his session at Cloud Expo, Alan Winters, U.S. Head of Business Development at MobiDev, presented a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to maximize project result...